Skip to main content
. 2024 Nov 5;30(11):e70109. doi: 10.1111/cns.70109

FIGURE 3.

FIGURE 3

ROS levels were increased in XDP‐derived fibroblasts and XDP‐treated SH‐SY5Y cells. (A) Two‐way ANOVA demonstrated a significant effect of genotype ([F (2, 24) = 244.5], p < 0.0001), and time ([F (12, 24) = 47.84], p < 0.0001) on ROS levels in XDP fibroblasts. As revealed by Tukey's test, ROS levels were increased in antimycin A‐treated fibroblasts compared with vehicle‐treated control fibroblasts (p < 0.0001). Additionally, there was a significant increase in ROS in vehicle‐treated XDP fibroblasts compared with control fibroblasts (p < 0.0001). XY graph represents the average ROS measured in fibroblasts derived from two individuals living with XDP (33,109 and 35,883) and two controls (36,175 and 33,362). (B) Two‐way ANOVA demonstrated a significant effect of treatment ([F (2, 24) = 25.66], p < 0.0001), and time ([F (12, 24) = 8.994], p < 0.0001) on ROS levels in SH‐SY5Y cells. As expected, Tukey's test revealed a significant increase in ROS in antimycin A‐treated cells compared with vehicle‐treated cells (p < 0.0001). Importantly, there was a significant increase in ROS in XDP‐treated cells compared with vehicle‐treated cells (p < 0.0001). ****p < 0.0001.